Distek Awarded U.S. Patent 8,903,673
News Feb 24, 2015
Distek, Inc. has been awarded U.S. Patent 8,903,673 for their modularity design and the individual position software control.
Distek’s patented, self-contained, modularity design is configurable for up to 8 positions when in use on the symphony 7100 “Bathless” Dissolution Instrument and 6 positions when in use on thesensIR 3200 “Bathless” Disintegrator. This modularity design allows users unprecedented ease and scalability.
“Distek is excited to have been awarded this patent which exemplifies our commitment to providing technically innovative products offering valuable feature benefits to our customer base,” says Jeff Brinker, President, Distek, Inc.
Brinker continued, “This patent in particular allows our customers a great deal of flexibility in the symphony 7100 and sensIR 3200 platforms in its modularity both mechanically as well as in the user interface design.”
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Allergy Amplifier Implicated in Asthma Also Intensifies Food AllergyNews
Scientist who previously reported that a small protein, aptly named histamine-releasing factor, played a pro-inflammatory role in asthma have now shown that it also serves as a “food allergy amplifier”. This work paves the way for blood tests to predict which patients will respond to allergy therapy, and strongly supports the idea that drugs designed to block HRF could prevent food allergy attacks.READ MORE